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Abstract 
 
 
Adrenocortical carcinoma is a very rare and aggressive endocrine tumor, which 
generally conveys poor overall 5-year survival. Worldwide incidence is estimated at 1-2 
million /year. Patients who suffer from ACC can present with symptoms of hormone 
excess, including Cushing’s syndrome, virilization, feminization and less frequently 
hypertension associated with hypokalemia. 
 In almost all cases, histopathological research can distinguish between 
adrenocortical adenoma and carcinoma, using one of the international classification 
methods. Other diagnostic techniques include hormone work up and imaging methods. 
Radical surgery is considered the therapy of choice in the first stages of ACC, and when 
surgery is not feasible, after incomplete resection or for metastatic disease, adjuvant 
mitotane is added. Control of excessive hormone production is a vital part of 
management in all patients. 
 Nevertheless, despite complete resection, there are high recurrence rates. 
Management of recurrent ACC should take place in a specialist center and the individual 
biology of each case of recurrence must be considered when making treatment decisions. 
Early detection of recurrent disease is important as well as close follow up with clinical 
examination and imaging. Liver, pulmonary and bone metastasis are most often involved 
in systemic recurrence and management usually consists of mitotane, with or without 
combination chemotherapy. Surgical resection only plays a limited role in systemic 
recurrence, and only in selected patients. Unfortunately, treatment for this aggressive 
tumor is still ineffective. 
 
 
 
 
 
 
 
3 
 
1. Introduction 
 
1.1. Epidemiology 
Adrenocortical carcinoma (ACC) is a rare disease, in contrast to the prevalence of 
adrenal incidentalomas, which occurs in at least 3 % of the population over the age of 50 
years. The precise incidence of ACC is a challenge itself because of its infrequent 
occurrence. However, according to Fassnacht et al., most authors estimate ACC to have 
an incidence of 1-2 per million population (1). Although, ACC is responsible for only 
approximately 0.2% of all cancer deaths in the United States annually, it is the second 
most aggressive endocrine malignancy behind anaplastic thyroid cancer. In addition, 
women seem to be more affected than men with a ratio about 1.5:1(2). 
ACC has been observed to have a bimodal distribution, with the first peak 
occurring in children younger than 5 years and the second and higher peak appearing in 
the fourth and fifth decades of life (3). In a study by Maluf et al., it was noticed that there 
is a significant incidence in Southern Brazil with 3.4 – 4.2 cases per million children 
under the age of 15 years, even though adrenocortical tumors are rare in childhood (4). 
 
1.2. Pathogenesis 
 
 The etiology of most cases of ACC is unknown, though it is understood that 
genetic factors and heredity play an important role in the occurrence of the tumor in some 
patients (3). Inherited risk factors for ACC include Beckwith-Wiedemann syndrome, Li-
Fraumeni syndrome, McCune-Albright syndrome, MEN- syndrome and familial 
adenomatous polyposis coli (Gardner syndrome). However, sporadic cases are more 
frequent (3,5). Molecular changes lead to the inactivation of the tumor suppressor genes 
as well as the activation of oncogenes.  The insulin growth factor II (IGF-II) system, 
located at 11p15 is highly associated with the pathogenesis of ACC (6). In addition, IGF- 
II has been found to be overexpressed in 90 % of patients with sporadic ACC compared 
to adrenal cortical adenomas (7). Moreover, the loss of heterozygosity (LOH) at 
chromosome region 11p15, which is related with higher risk of tumor recurrence, is more 
common in ACC than in adrenal adenomas (6).  
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1.3. Clinical presentation 
 
The majority of patients with ACC (60%) presents with signs and symptoms of 
adrenal steroid excess. Rapidly progressing Cushing’s syndrome with or without 
virilization is the most frequent presentation (1). This can be a sudden developing disease 
with skin atrophy, hyperglycemia, muscle weakness, hypertension and psychiatric 
disorders (5). The evolution is rapid, generally with less than one year lapsing from the 
first clinical changes to advanced Cushing’s syndrome (8).  
In addition, androgen-secreting ACCs in women present with hirsutism, male-
pattern baldness, low voice and oligomenorrhea of recent onset. Estrogen-secreting 
tumors are less frequent (5 -10 % of male patients), but when present are almost 
pathognomonic for ACC. They produce gynecomastia and testicular atrophy in males. 
Rare aldosterone –producing adrenocortical carcinomas present with severe hypertension 
and profound hypokalemia (1,5). 
Moreover, patients with a non-functioning ACC usually have symptoms of 
abdominal discomfort, abdominal fullness, back pain and gastrointestinal complaints 
such as nausea and vomiting. In those cases without clinical hormone excess, the most 
common presentation is related to tumor growth and intrusion on the surrounding 
structures. A small number of patients present with fever, weight loss and loss of appetite 
and in a few cases, a palpable mass can be felt on physical examination. In fact, it is 
possible for patients to have a large tumor without much evidence of systemic disease 
besides signs and symptoms of hormone excess (1,5, 8). In addition, Symeonidis et al. 
state in a case report that the clinical picture of an acute abdomen is an extremely rare 
presentation of adrenocortical carcinoma, which requires the spontaneous rupture or 
infarction of a large adrenal mass (9). Furthermore, adrenocortical carcinoma tends to 
spread by both hematogenous (most frequently the lungs, followed by the liver and bone 
in some cases) and lymphatic route (to regional and paraaortic lymph nodes). Metastases 
to the other adrenal gland, or the occurrence of bilateral adrenocortical carcinoma may 
develop in around 4 % of cases (5). 
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1.4. Diagnosis 
 
The variable clinical manifestations of adrenal carcinomas make the correct 
diagnosis a challenging procedure. The various diagnostic tests include hormonal 
workup, imaging modalities and histopathology. 
 
Hormonal work-up 
 
With patients presenting with adrenal lesions, endocrine assessment is of the 
utmost importance in the initial elective workup. The diagnostic evaluation of ACC 
depends upon the clinical appearance. Cushing’s syndrome at time of presentation 
necessitates the measurement of urinary cortisol excretion for 24 hours, early morning 
cortisol after 1mg dexamethasone at 23:00 hours the night before (known as the 1mg 
overnight suppression test), or the late night (salivary) cortisol level. A positive (elevated) 
result of one of these tests confirms Cushing’s syndrome (5, 9).  
Abnormal steroidogenesis (depicted by elevated levels of cortisol precursors such 
as 17-OH- progesterone and 17-OH-pregnenolone) with gas chromatography separation 
of 17-ketosteroids establishes the clinical diagnosis of adrenocortical carcinoma. In 
addition, elevated plasma levels of DHEAS (dehydroepiandrosterone sulphate) and 
testosterone in women and 17--estradiol in men are markers for ACC, however, their 
specificity is unknown (5). 
 
Imaging 
 
Proper imaging of the tumor and possible metastases is required for best patient 
care. For differential diagnosis of an adrenal mass, computerized tomography (CT) and 
magnetic resonance imaging (MRI) are currently equally reliable. Although these 
techniques cannot determine the precise identity of the mass, both are able to show clear 
evidence of a benign tumor in most cases when performed appropriately. Most ACCs 
usually have higher density (i.e. lower lipid content) and are inhomogeneous, with 
irregular margins and irregular enhancement of solid components after intravenous 
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contrast media. In addition, calcifications can often be seen. Local invasion or tumor 
extension into the inferior vena cava (IVC), as well as lymph node or other metastases 
(lung and liver) are frequently found in advanced ACC. Measurements of Hounsfield 
Units (HU) in unenhanced CT is of great value in differentiating malignant from benign 
adrenal lesions (1, 3). ACCs display a considerably higher density on non-contrast CT 
than adenomas, with specificity for discerning adenoma from carcinoma of 100 % and 
96.9%, using 10 and 20 HU cutoffs, respectively (8). However, lipid-poor benign 
adenomas show frequently unenhanced HU values more than 10 HU. To improve the 
differentiation of these lipid-poor adenomas from ACC, delayed contrast-enhanced CT is 
used, analyzing washout of contrast medium. Fassnacht et al. report that “adrenal lesions 
with an attenuation value of  >10 HU in unenhanced CT or on enhancement washout of < 
50 % and a delayed attenuation of >35 HU (on 10- 15 minute delayed enhanced CT) are 
suspicious for malignancy” (1). 
Another reliable method for demonstrating adrenal lesions is MRI with 
gadolinium and chemical shift technique. Once more, the fat content provides an 
indication as to whether the tumor is benign or malignant. ACCs are usually isointense 
with liver on T1-weighed image, with intermediate to increased intensity on T2-weighed 
sequences (1, 3). Enhancement with after gadolinium is characteristic and washout is 
typically slow. Based on these qualities, the sensitivity of MRI to distinguish between 
benign and malignant adrenal masses is 81-89% with a specificity of 92-99% (1). If there 
is a suspicion of vascular involvement, MRI should be conducted before surgical 
resection as it better in evaluating the extent of vascular invasion, especially into the IVC 
with right adrenal tumors (3). 
Moreover, the use of [18F] fluorodeoxyglucose (FDG) – positron emission 
tomography (PET) is not suggested in baseline routine evaluation. High uptake of 18 F-
FDG demonstrates increased glucose metabolism and indicates malignancy, however, it 
does not distinguish between ACC and other tumors with high metabolic activities. In 
addition, although adrenal scintigraphy with 
131
I-6-iodomethyl-norcholesterol (NP59) 
was used in the past to visualize adrenal tumors, it is a time-consuming technique and 
associated with a high radiation dose. A new method for adrenal imaging employing 
metomitade as radiotracer is promising as it specifically binds to adrenal 11 -
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hydroxylase and aldosterone synthase and, therefore, uptake indicates the adrenocortical 
origin of a lesion (1, 5). 
Imaging is important not only for characterizing adrenal lesions but also for 
staging. Approximately one third of patients present initially with metastases of which 
lung and liver are the most frequent sites. Therefore, high-resolution CT of chest and 
abdomen (alternatively MRI) is mandatory. CT is better in detecting lung lesions, while 
MRI is more sensitive for liver lesions. In cases of uncertainty, FDG-PET can be of great 
help. With the presentation of bone pain or suspected brain metastases, a bone 
scintigraphy followed by conventional x-ray studies in regions with high uptake and a 
cerebral CT/MRI should be performed (1). 
Furthermore, fine-needle biopsy should only be performed if the tumor cannot be 
surgically resected and medical therapy requires pathological evaluation of the tumor. 
Biopsy for ACC is almost never warranted, as it is associated with risk of needle-track 
metastasis (1).  
 
Histopathology 
 
The pathological diagnosis of ACC may be problematic to determine due to the 
lack of clear-cut morphological criteria as well as the difficulty in distinguishing small 
ACCs without local spread or distant metastases from a benign adenoma. Therefore, 
several multiple parameters have been proposed for establishing malignancy. Among 
these, the Weiss criteria, first proposed in 1984, is most commonly used (3). It combines 
nine morphological parameters: three parameters related to tumor structure (description 
of cytoplasm, diffuse architecture, necrosis), three related to cytology (atypia, atypical 
mitotic figures, mitotic count), and three related to invasion (veins, sinusoids, tumor 
capsule) (1). It is uncertain whether the presence of a greater number of criteria is 
associated with a worse prognosis but tumors with higher Weiss scores clinically often 
behave more aggressively (3). 
Immunohistochemistry also offers valuable information. Ki-67 expression can be 
used both for differentiating benign from malignant tumors and for prognosis in ACC. A 
cut off value between adenomas and ACCs ranging from 1.5% to 4% has been reported. 
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A high Ki-67 index (> 10%) is strongly associated with a poor clinical outcome, a 
shortened disease-free status and a decreased overall survival (1,7). 
In addition, other markers such as Melan A, D11, inhibin , and SF-1 are useful 
in determining the adrenocortical origin of the tumor, whereas ACCs are typically 
negative for chromogramin A, cytokeratins and S100. A number of new markers – loss of 
heterozygosity (LOH) at 17p13, IGF-2 overexpression, cyclin E, matrix 
metalloproteinase-2 (MMP-2), telomerase activity, topoisomerase II , and N-cadherin- 
have been used to differentiate between benign and malignant adrenal lesions. However, 
none of these markers have been recognized to be reliable (1). 
 
 
1.5. Staging 
 
Various staging systems have been introduced for classification of ACC to 
evaluate the prognosis and to select treatment strategies. 
 
TABLE 1: Staging systems of ACC according to the criteria UICC (Union Internationale 
Contre Cancer) and the ENSAT (European Network for the Study of Adrenal Tumors. 
 
Stage UICC/WHO 2004 ENSAT 2008 
I T1, N0, M0 T1, N0, M0 
II T2, N0, M0 T2, N0, M0 
III T1-2, N1, M0 
T3, N0, M0 
T1-2, N1, M0 
T3-4, N0-1, M0 
IV T1-4, N0-1, M1 
T3, N1, M0 
T4, N0-1, M0 
T1-4, N0-1, M1 
 
T1: tumor ≤ 5 cm; T2: tumor > 5cm; T3: tumor infiltration in surrounding tissue; T4: 
tumor invasion into adjacent organs or venous tumor thrombosis; N0: no positive 
lymph nodes; N1: positive lymph node(s); M0: no distant metastasis; M1: distant 
metastasis. 
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1.6. Treatment 
 
  A multidisciplinary approach is required for the management and treatment of 
patients with ACC, both at initial presentation and at disease recurrence. 
 
Surgery 
 
Surgery and adjuvant therapy are two important and critical issues to consider 
when dealing with patients with localized ACC. In all patients with stage I-II and most 
patient with stage III, complete resection is possible. However, surgical resection of ACC 
is challenging, and requires surgeons to be skillful in order to avoid tumor spillage and 
incomplete resection (1). Open adrenalectomy (OA) is the most widely accepted 
approach in the treatment of ACC. Stigliano et al. support is that open adrenalectomy is 
the only curative option when a margin-free complete resection (Ro resection) is 
achieved and it is of predictive value for long-term survival. Nonetheless, subsequent 
follow-up commonly (85%) shows regional recurrence or presence of distant metastases 
even after complete resection of the tumor (6).  
In addition, laparoscopic adrenalectomy (LA) while technically achievable is still 
greatly contentious due to tumor seeding that can occur as a result of the procedure. It is 
especially believed to occur in adrenal masses that appear malignant radiologically and 
therefore, LA is contraindicated in such cases. Most authors report that there is an 
increased rate of local recurrence and peritoneal carcinomatosis in those receiving 
laparoscopic adrenalectomy, postulating loss of capsule integrity and port site seeding as 
probable causes (3, 8).   
Moreover, for tumors invading adjacent tissues or organs, concomitant resection 
of kidneys, liver, spleen, pancreas, stomach, colon, wall of the vena cava should be 
considered. Surgery often requires excision en bloc of the ipsilateral kidney, spleen, and 
partial pancreatectomy in the case of a left adrenal cancer and a partial hepatectomy for a 
right adrenal cancer. Cardiac bypass technique is sometimes needed for complete tumor 
removal in cases of a tumor thrombus in the IVC or the renal vein. The abdominal lymph 
nodes must also be excised to achieve complete resection of ACC (1, 6). 
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Further treatment is mandatory in patients where the resection was incomplete 
and a second surgical approach is not practical. For recurrent disease, reoperation is vital 
for the purpose of radical resection, especially if sufficient time (arbitrarily defined as 6 
months to a year) has elapsed since the initial operation and if the patients are fit for 
reoperation (1,6,7). Metastatic disease debulking surgery, which removes as much of the 
tumor as possible, aids in reducing the mass effect, as well as the hormonal excess 
produced by the tumor (6). According to Fassnacht et al., tumor debulking, in most 
patients, is not an acceptable treatment option due to the fact that the recuperation from 
an extensive surgery is usually slow and postpones administration of systemic therapy. 
They also add that patients with profound Cushing’s s syndrome may profit from 
debulking surgery as it can reduce the tumor mass and hormone excess (1). However, 
medical palliation alone is the treatment of choice in patients with widely metastatic 
disease or rapidly enlarging tumors at diagnosis (8). 
 
Medical treatment 
 
The risk of post-operative recurrence is perhaps as high as 60-80%, and adjuvant 
therapy is recommended for most patients with ACC. Mitotane alone or mitotane in 
combination with chemotherapy serves as conventional or first line treatments. If 
complete resection of the primary tumor and all metastases can be performed at the time 
of diagnosis (even if two steps are needed), it should be followed by adjuvant mitotane 
therapy. In cases where surgery is not possible, mitotane is the backbone therapy (1,7).  
Mitotane (1,1-dichloro-2- (o-chlorophenyl)-2-(p-cholophenyl)-ethane or o’p’-
DDD) is an isomer of the insecticide DDT (dichlorodiphenyltrichloroethane). It was first 
described in 1948 when it was shown to produce adrenal atrophy in dogs. This drug acts 
by inhibiting 11-hydroxylation and cholesterol side chain cleavage in the mitochondria 
of steroidogenic cells, therefore blocking cortisol synthesis hence decreasing both plasma 
and urine steroid levels (3,6,12). Mitotane exhibits a cytotoxic and degenerative effect on 
the fasciculata and reticularis areas of the adrenal cortex while the zona glomerulosa is 
barely affected (6,11). Metabolic activation is necessary for its adrenolytic effect. 
Mitotane is formulated as 500 mg tablets (Lysodren) for oral administration and is poorly 
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absorbed as 60 % is excreted in stool, usually unchanged while 40% concentrates in liver, 
brain, adipose and adrenal tissues. Attainment of therapeutic serum levels is delayed for 
12-14 weeks after induction of therapy due to accumulation of the drug in adipose tissue. 
On the other hand, mitotane is released slowly from adipose tissue and can be measured 
in the serum months after cessation of the drug (3,5). The drug’s accumulation in adipose 
tissue increases the plasma half-life from 2 -3 hours at the beginning of the therapy to 18-
159 days (6). 
A preferable administration schedule is to start with 1.5 g/day and to rapidly 
increase the daily dose to 4.5 to 6-g/ day within 3 to 4 days. The dose is adjusted 
according to the mitotane plasma concentration and lower doses are needed as the body 
stores become saturated. In patients who receive long-term therapy, mitotane doses 
should be adjusted every 4- 8 weeks until a stable level (14– 20 mg/L) is reached with 
tolerable side effects and subsequently at 3-month intervals (3, 5). It is critical to note that 
blood levels > 20mg/L are associated with higher risk of toxicity (1).  
Adverse effects of mitotane treatment are diverse and common; most are 
correlated to its plasma concentrations. However, some gastrointestinal side effects such 
as anorexia, nausea, vomiting, and diarrhea, appear to be related to the daily dose 
(especially in patients receiving 2 g or more per day). In such cases, the use of 5-
hydroxytryptamine blockers and loperamide may be beneficial. At higher doses, 
neuromuscular manifestations including ataxia, speech disturbance, muscle tremors, 
confusion, somnolence, and vertigo may develop. Mitotane treatment needs to be halted 
in cases of severe side effects, and can be restarted at lower dose when symptoms 
improve.  
 In addition, mitotane treatment causes adrenal insufficiency due to its adrenolytic 
effects as well as the increase of metabolic clearance of glucocorticoids and the 
concentration of cortisol- binding globulin (CBG) thus necessitating glucocorticoid 
replacement (50 -80 mg hydrocortisone daily). Mineralocorticoid secretion is less altered 
as mitotane mainly targets the cells of the zona fasciculata and the zona reticularis. 
Though, if mitotane is used for an extended period, renin concentration/ activity needs to 
be observed and may require replacement with fludrocortisone. Furthermore, some 
patients can profit from testosterone replacement as mitotane elevates the levels of sex 
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hormone binding globulin, which brings about low free testosterone concentrations in 
males. In most patients, alterations in thyroid hormones will ensue (low free T4 and low 
TSH), thus requiring monitoring every few months, and replacement when necessary (1, 
3). Regardless of the many side effects of mitotane, most patients can be managed with 
tolerable toxicity for a vast period of time and the treatment needs to be prolonged for 
one to two years after the tumor regression (5).  
Excess secretion of hormonal steroids due to ACC commonly disturbs the quality 
of life, especially Cushing’s syndrome that usually produces hypokalemia, muscle 
wasting, osteoporotic fractures and infectious complications. In some patients, mitotane 
treatment alone is inadequate in regulating the hormonal excess because of its slow onset 
of action and its dose-limiting toxicity. Therefore, adrenostatic drugs such as 
ketoconazole, metyrapone, and etomidate have been efficaciously employed to inhibit 
steroidogenic enzymes and to return circulating cortisol into its normal range (1). 
Furthermore, since less than 50 % of tumors respond to cytotoxic treatment and 
only for a short period of time, a large number of patients need salvage therapies, and the 
recommended first-line treatment in advanced ACC is a combination of etoposide, 
doxorubicin, cisplatin plus mitotane (EDP/M) (1, 5). 
 
Radiotherapy 
 
Radiotherapy (RT) is a valuable adjuvant therapy in all patients with ACC who 
receive surgical treatment since most resections are unsuccessful (4). However, there are 
limitations to its use in ACC. First of, ACCs are not very radiosensitive tumors. 
Secondly, they are in the vicinity of radiosensitive viscera such as the small bowel, 
kidney and spinal cord. Nonetheless, RT has an important value in the treatment of 
metastatic ACC, especially in the presence of bone disease, as well as improving 
symptoms in patients with massive abdominal tumors that impossible to remove 
surgically. At large, most authors recommend adjuvant RT to lessen the high probability 
of local disease relapse seen in ACC (8). 
The lack of strong evidence supporting RT has resulted in a variety of treatment 
recommendations. Lebastchi et al. state that the German ACC group presently 
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recommends radiotherapy in the following cases:  1) all patients with incomplete (R1- 
detectable microscopic tumor residues after surgery or R2- macroscopic visible residual 
tumors) or uncertain (Rx) resections, 2) all patients with stage III disease regardless of 
resection adequacy, 3) strong consideration in cases of  > 8 cm tumor size, Ki67 index > 
10 %, and invasion of adjacent vasculature, even in cases of complete resection. At 
present, there are no specific guidelines for RT usage in patients with complete tumor 
removal (R0)(6, 8).  
Adjuvant RT should begin no later than 3 months after surgery. The 
recommended fractionation protocol is made of single doses of 1.8-2.0 Gy per fraction on 
5 days per week for a 5-6 weeks period treatment. The preferable total doses should range 
from 50 to 60 Gy and should not be lower than 40 Gy (8). Some authors advocate the use 
of mitotane treatment in conjunction with radiotherapy for patients on whom R1 and Rx 
resection was performed. However, mitotane dosages should be < 3g/day to avoid   
serious hepatic toxicity (6).  
 
Targeted therapies 
 
Recent innovations in the genetic alterations associated with ACC onset and 
progression made the discovery of several potential molecular targets possible for 
selective therapy of ACC such as IGF-IR antagonists, -catenin antagonists, SF-1 inverse 
agonists, etc. (4, 6). As 90 % of ACCs patients express high levels of IGF-II acting via 
IGF-I receptor (IGF- IR), thus blockage of the IGF- IR is an important possibility to 
explore in treatment of these patients (1,6).  
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1.7. Prognosis 
 
Even though many breakthroughs regarding ACC have been made, prognosis is 
still very poor and about 70 % of patients present with extra-adrenal disease at the time of 
diagnosis (8). The most critical factor for the prognosis of patients with ACC is an early 
diagnosis, which can greatly improve the survival rate (6). The average survival time of 
patients not receiving treatment is approximately 2.9 months and mostly relies on the size 
of the tumor (5). Three factors have been attributed to a shorter survival: older age at 
diagnosis, stages III (involvement of local lymph nodes) to IV (local organ invasion or 
distant metastases) disease, and cortisol hypersecretion. (4). 
Furthermore, prognosis still mainly depends on tumor stage and 5-year survival 
rates are 84% for stage I, 63% for stage II, 51% for stage III and 15% for stage IV. Large 
tumor size (diameter > 12 cm) has been implicated in poor survival rate after complete 
resection and the 5 year- survival rate being as low as 5 %. Also, approximately 70% to 
80 % of patients relapse after resection. In addition, a high mitotic rate, tumor necrosis, 
atypic mitotic figures, high Ki-67 values and evidence for mutated TP53 have been 
associated with advanced ACC and poor prognosis (1).  
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2. Aim of study 
 
The purpose of the study is to present the treatment results of patients at the ACC referral 
center – KBC University Hospital Zagreb and to highlight the approach in the 
management of ACC in terms of diagnosis, follow-up, and treatment. 
 
3. Methods 
 
In a retrospective study, during the period of 1.1.2005 to 1.9.2013, 18 patients, 
consisting of 5 males and 13 females, were diagnosed with adrenocortical carcinoma at 
the ACC referral center – KBC University Hospital Zagreb. The patients had a mean age 
of 44 years (range, 17-74 years). ACC was diagnosed by utilizing the appropriate 
hormonal work-up, imaging methods and histopathological analysis. Stage of disease was 
assigned according to the ENS@T system given in Table 1.  
The criteria for the histologic diagnosis of ACC was based on the Weiss scoring 
system which consist of nine histological parameters: high nuclear grades (nuclear grades 
III and IV), mitotic rate >5/50 high power fields (HPF), atypical mitotic figures, clear 
tumor cell cytoplasm (less than 25% tumor cells), diffuse architecture (greater than 33% 
of tumor), necrosis, venous invasion, sinusoidal invasion, and capsular invasion.
 
A tumor 
is labeled malignant when it meets three or more of the stated criteria. Additionally, 
immunostaining for the proliferation marker Ki- 67 was performed in all patients.  
Moreover, 16/18 patients underwent radical surgical resection (Ro). Afterwards, 
selected patients with a Ki- 67 index greater than 10 % (11/18) received adjuvant therapy 
with mitotane. From March 2010, the concentration of mitotane received by patients was 
achieved according to the Lysosafe program, which included 14/18 patients. The aim was 
to reach mitotane plasma levels of 14-20 mg/L, and therefore, the mitotane doses were 
adjusted accordingly. Furthermore, chemotherapy was given if there was disease 
progression while receiving mitotane and in patients with metastatic disease at the time of 
diagnosis. One of the patients was treated with a combination chemotherapy, which 
consisted of etoposide, doxorubicin and cisplatin as well as the administration of 
mitotane (EPD/ M). 
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4. Results 
 
4.1. Clinical characteristics of patients with ACC 
 
Adrenocortical carcinoma was diagnosed as an adrenal incidentaloma in 13 out of 
18 patients. In addition, 5 out of 18 (28 %) presented with and were diagnosed due to 
symptoms of hypersecretion of hormones. Functional tumors secreting increased levels of 
one or more hormones were identified in 12 patients (67%).  Androgen- secreting tumors 
were the most common functional tumors, comprising 50 % (6/12), followed by cortisol- 
secreting tumors in 33% (4/12), 17- OHP in 17% (2/12), aldosterone- secreting tumors in 
17% (2/12), and estradiol- secreting tumors in 8% (1/12), out of which mixed hormonal-
secreting tumors were found in 3 cases.  The tumor was located on the left in 11 and right 
in 7 patients. The median size of the tumor was 92 mm with the range of 45 to 160 mm. 
Moreover, at the time of diagnosis, stage I tumors were found in one patient (6 %), stage 
II in 9 (50 %), stage III in 6 (33 %), and stage IV in 2 (11 %) (Figure 1).  
 
FIGURE 1: Stages at diagnosis 
 
Stage I (1/18 – 6%), stage II (9/18 – 50%), stage III (6/18- 33%) & stage IV (2/18 – 
11%). 
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4.2. Surgical treatment  
Surgical management consisted of curative resection (Ro resection – no gross 
residual disease) and was performed in 17 out 18 patients (94%). Open adrenalectomy 
was performed in 11 patients and laparoscopic adrenalectomy in 7 patients. During the 
surgical procedures and in the post-operation period, no complications were encountered. 
 
4.3. Pathohistological findings 
 
The Ki-67 proliferation index was greater than 10 % in 11 out of 18 patients (61 
%) with a median of 16 % and a range of 1 to 65%. In addition, 8/18 patients (44%) had a 
high mitotic index ≥ 9/50 HPF. The median Weiss score was 6 with a range from 3 to 8 
(Figure 2).  
 
FIGURE 2: Ki-67 expression and Weiss score 
 
Ki-67 >10% in 11/18 patients (median 16%, range 1–65%) and a median Weiss score: 6 (range 
3–8). 
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4.4. Medical treatment of patients with ACC 
 
The time that elapsed from the diagnosis to the operation was 40.7 ± 15.8 days 
and from the surgery to the mitotane therapy 48.8 ± 27.6 days. Mitotane was initiated 
using 1.5 g/day and was rapidly increased over the next 3 to 4 days to reach the dosage of 
4.5 to 6-g/ day. All patients that were included in the Lysosafe program (14/18) reached 
the optimum mitotane concentration, which is between 14 to 20 mg/L. Mitotane alone 
was used in 13 patients; and mitotane plus etoposide, doxorubicin and cisplatin (EPD/ M) 
were utilized in one patient. Adverse effects due to mitotane treatment were observed in 8 
patients. These mainly included gastrointestinal symptoms, dizziness, increased levels of 
cholesterol and high GGT (Gamma-glutamyl transpeptidase) ranging from 2x to 8x 
greater than the normal values. 
 
4.5. Treatment outcome of patients with ACC 
 
The median time of follow-up was 19 months and it ranged from 1 to 102 months. 
Moreover, 2/18 patients (11%) died; one because of advanced disease and the other the 
cause of death was not related to ACC. In addition, recurrence occurred in two patients 
(11%). With one of the patients, local recurrent tumor was surgically treated and with 
another one there was a solitary metastasis on the lungs, which was resected on two 
occasions. With the other patients (78%) there was no progression of the disease. 
 
 
5. Discussion 
 
 This study presented results of 18 patients who were diagnosed with 
adrenocortical carcinoma at the ACC referral center – KBC University Hospital Zagreb.  
Most of our patients were diagnosed with adrenal incidentalomas (13/18). These are 
adrenal masses of >1 cm in diameter found incidentally on imaging performed for 
unrelated reasons. These incidentally discovered adrenal masses have increased due to 
widespread use of imaging procedures and new diagnostic techniques.  In addition, only 
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5/18 patients presented with symptoms of hormone hypersecretion.  Nonetheless, 12/18 
patients were later diagnosed with functional tumors, of which androgen-secreting tumors 
were the most prominent, followed by cortisol- secreting tumors. However, many studies 
have showed that rapidly progressing Cushing’s syndrome with or without virilization is 
the most frequent presentation in the majority of patients. 
Many ACC patients suffer from a locally advanced or metastatic disease at the 
time of diagnosis.  Stage II disease was predominant in our patients (9/18), followed by 
stage III (6/18), stage IV (2/18) and lastly, stage I (1/18).  Both patients with stage IV 
disease underwent surgical resection and received adjuvant therapy; nevertheless, they 
died after 11 and 18 months follow-up respectively. The rest of the patients underwent 
radical surgical resection (Ro), which has been the mainstay treatment of ACC tumors 
and has been shown to improve the survival rates. Open adrenalectomy was the main 
procedure performed  (11/18) when compared to laparoscopic adrenalectomy (7/18).  
Usually laparoscopic surgery in ACC is feared due to the seeding of the tumor cells in the 
abdomen that can occur as well as the high rates of local recurrence due to the loss of 
capsular integrity. The resection status (R0, R1, R2) is a major predictor of prognosis for 
ACC. A margin-free complete resection (R0 resection), in fact, provides the only means 
to achieve long-term survival. To obtain an R0 resection of a locally advanced ACC, it is 
often necessary to resect parts of the adjacent organs such as the wall of the vena cava, 
liver, spleen, colon, pancreas and/or stomach.  
In addition, mitotane has been used principally as the agent of choice in treating 
patients with ACC. By following serum mitotane levels, the lowest dose is given that 
achieves a ‘therapeutic’ level (>14mg/L). Since the majority of the patients (80%) 
received mitotane adjuvant therapy and since 14/18 went into remission, the importance 
of mitotane in prolonging survival cannot be stressed enough. In a study by Terzolo et al., 
the maintenance of plasma mitotane concentration ≥ 14mg/L was shown to predict tumor 
response and better survival rates in patients with ACC, especially in advanced disease 
(13). In selected cases, other combination chemotherapy can be given such as EPD/ M 
(etoposide, doxorubicin, cisplatin plus mitotane), which was administered to one patient. 
Moreover, in case of painful metastasis, palliative radiotherapy is an option, 
especially in bone lesions. However, none of our patients were treated with radiotherapy 
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since ACCs are not very radiosensitive tumors as well as their location, which is in close 
proximity to radiosensitive viscera such as the small bowel, kidney and spinal cord. 
Nevertheless, radiotherapy has a significant role in the treatment of metastatic ACC, 
particularly in the presence of bone disease, as well as improving symptoms in patients 
with large abdominal tumors that cannot be removed surgically. 
Even though many discoveries have been made regarding ACC, prognosis is still 
very poor and the majority of patients present with extra-adrenal disease at the time of 
diagnosis. The most essential aspect for the prognosis of patients with ACC is an early 
diagnosis, which can significantly improve the survival rate. Three factors have been 
associated to a shorter survival rate: older age at diagnosis, stages III to IV disease, and 
cortisol-secreting tumors. In addition, the only parameter related to patients’ survival 
rates is a Ki-67 proliferation index of more than 10%.  Ki-67 >10% was found in 11/18 
patients (61%), and it is strongly associated with a poor clinical outcome, a shortened 
disease-free status and a decreased overall survival. A 5 year- follow-up could only be 
documented with five patients, out of which two died (diagnosed at stage IV) and three 
went into remission (diagnosed at stages I &II). Additionally, 13/18 patients have not yet 
reached the 5 year- follow-up necessary for this study to well assess the overall 5-year 
survival rates. 
 
6. Conclusion 
 
ACC is a rare endocrine tumor that has to be taken care of in a specialized center 
with great experience in treating this tumor. Radical resection with adjuvant mitotane 
therapy in patients with high-risk progression of the disease is the foundation of a 
successful treatment. In our cohort, 14/18 patients had no recurrence of disease after Ro 
resection and adjuvant mitotane therapy. In addition, 2/18 patients died after 11 and 18 
months follow-up respectively, and 2/18 had recurrence of the disease. However, our data 
is limited due to a short follow-up period and therefore, we cannot assess the overall 5-
year survival rates. 
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